Pulmonx Corp
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
LUNG$2.800.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(14,448) | $(13,749) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 5,612 | 5,673 |
| Inventory write-down (recovery), net | (46) | 163 |
| Depreciation and amortization expense | 278 | 423 |
| Amortization of debt discount and debt issuance costs | 11 | 16 |
| Net accretion of discounts on marketable securities | (206) | (393) |
| Non-cash lease expense | 360 | 701 |
| Net changes in operating assets and liabilities: | ||
| Accounts receivable | (721) | 1,363 |
| Inventory | 406 | (1,084) |
| Prepaid expenses and other current assets | 308 | 266 |
| Other assets | (369) | 26 |
| Accounts payable | 505 | 1,635 |
| Accrued liabilities | (4,891) | (5,981) |
| Income taxes payable | 24 | (22) |
| Lease liabilities | (37) | (840) |
| Deferred revenue | (8) | 8 |
| Net cash used in operating activities | (13,222) | (11,795) |
| Cash flows from investing activities | ||
| Purchases of investments | (3,921) | (13,806) |
| Maturities of investments | 20,535 | 11,750 |
| Purchases of property and equipment and internal software development costs | (301) | (451) |
| Net cash provided by (used in) investing activities | 16,313 | (2,507) |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options | 110 | 56 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 554 | 808 |
| Net cash provided by financing activities | 664 | 864 |
| Effect of exchange rate changes on cash and cash equivalents | (105) | 48 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 3,650 | (13,390) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 71,162 | 83,784 |
| Cash, cash equivalents, and restricted cash at end of the period | $74,812 | $70,394 |
| Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets: | ||
| Cash and cash equivalents | $74,555 | $70,158 |
| Restricted cash | 257 | 236 |
| Cash, cash equivalents, and restricted cash in consolidated balance sheets | $74,812 | $70,394 |
| Supplemental non-cash items: | ||
| Purchases of property and equipment in accounts payable and accrued liabilities | $9 | $100 |
| Amount receivable from exercise of common stock options | $— | $1 |
| Supplemental disclosure of cash flow information: | ||
|---|---|---|
| Cash paid for income taxes | $109 | $170 |
| Cash paid for interest | $788 | $875 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.